Advertisement


Laurie H. Sehn, MD, MPH, on DLBCL: Trial Results on the Prognostic Significance of MYC

2018 ASH Annual Meeting & Exposition

Advertisement

Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses a study by the Lunenburg Lymphoma Biomarker Consortium that confirmed previous reports on the negative prognostic impact of an underlying MYC-translocation for both progression-free and overall survival in diffuse large B-cell lymphoma (Abstract 344).



Related Videos

Leukemia

Jennifer Ann Woyach, MD, on CLL: Results From the Alliance North American Intergroup Study

Jennifer Ann Woyach, MD, of The Ohio State University, discusses trial findings on ibrutinib alone or in combination with rituximab compared with bendamustine plus rituximab in unt...

Lymphoma

Steven M. Horwitz, MD, on PTCL: Results From the ECHELON-2 Trial

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III findings on brentuximab vedotin and CHP vs CHOP in the front-line treatment of patients with C...

Skin Cancer
Lymphoma

Steven M. Horwitz, MD, on PTCL and CTCL: Trial Results on Cerdulatinib

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase IIa study findings on the novel SYK/JAK inhibitor cerdulatinib for relapsed/refractory peripheral ...

Myelodysplastic Syndromes

Mikkael A. Sekeres, MD, on MDS: Results From the Medalist Trial

Mikkael A. Sekeres, MD, of the Cleveland Clinic, discusses phase III study findings on luspatercept to treat anemia in patients with very low-, low-, or intermediate-risk myelodysp...

Hematologic Malignancies

Alexander B. Pine, MD, PhD, on Practices and Preferences for Anticoagulant Therapy in Treating VTE

Alexander B. Pine, MD, PhD, of Yale School of Medicine, discusses a survey gathering data on health-care providers’ practices and preferences in using direct oral anticoagulant the...

Advertisement

Advertisement



Advertisement